Miniatura

Fitxers

710221.pdf (1.58 MB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2020-07-31

Tots els drets reservats

Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/183733

Clinical evaluation of allogeneic eye drops from cord blood platelet lysate

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.2450/2020.0130-20

Resum

Background - Current treatments for several corneal lesions show limited efficacy. Here we report the clinical evaluation of the efficacy of a novel eye drop preparation produced in a public cord blood (CB) bank. Material and methods - In a multicentre, retrospective, consecutive case study we evaluated 33 patients (46 eyes) unresponsive to conventional treatments who required urgent intervention. The patients were given allogeneic eye drops obtained from cord blood platelet lysate (CBED) to treat severe ocular surface lesions under a compassionate use protocol. The CBED were prepared from CB units donated for haematopoietic stem cell transplantation that did not contain the minimum stem cell dose required for this use. Patients were grouped by acute conditions (neurotrophic ulcers: group I; other corneal ulcers: group II; corneal burns: group III), and chronic conditions (ocular graft-versus-host disease: group IV; severe dry eye syndrome: group V). The patients received one or two drops of the product to the affected eye four to six times per day for 19 days. A further 19-day cycle of treatment could be repeated according to the initial clinical response. Results - Patients received a median of 19 CBED vials (interquartile range 19-57, range 19-442) to complete the therapy. Group I-II-III patients showed full and partial ulcer recovery in 25 (78%) and six (19%) eyes respectively. One eye (3%) did not respond to treatment. For groups IV-V improvement was reported for 12 (85%) eyes and lesions worsened on treatment in both eyes (15%) of one patient. No severe adverse events were directly attributed to CBED. Discussion - Promptly available CBED resulted in a well-tolerated allogeneic treatment that showed evidence of efficacy in this cohort of patients. These positive results support further studies on CBED from platelet lysate as a novel product of CB banks. A prospective clinical trial in neurotrophic keratitis (NCT03084861) is ongoing to confirm these preliminary data. Keywords: cord blood, eye drops, corneal ulcers, neurotrophic keratitis, dry eye.

Matèries

Malalties de la còrnia

Matèries (anglès)

Cornea diseases

Citació

Col·leccions

Articles publicats en revistes (Cirurgia i Especialitats Medicoquirúrgiques)

Citació

SAMARKANOVA, Dinara, MARTÍN, Sara, BISBE, Laia, PUIG, Javier, CALATAYUD PINUAGA, Marta, RODRIGUEZ GÓMEZ, Luciano, AZQUETA, Carmen, COLL, Ruth, CASAROLI MARANO, Ricardo pedro, MADRIGAL, Alejandro, REBULLA, Paolo, QUEROL GINER, Sergi, Barcelona CBED Study Group.. Clinical evaluation of allogeneic eye drops from cord blood platelet lysate. _Blood Transfusion_. 2020. Vol. 19, núm. 4, pàgs. 347-356. [consulta: 20 de gener de 2026]. ISSN: 1723-2007. [Disponible a: https://hdl.handle.net/2445/183733]

Exportar metadades

JSON - METS

Compartir registre